[CTLT] Catalent, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 2.96 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 26.9 Change: 0.56 (2.13%)
Ext. hours: Change: 0 (0%)

chart CTLT

Refresh chart

Strongest Trends Summary For CTLT

CTLT is in the medium-term down -16% below S&P in 1 year. In the long-term up 34% in 2 years and up 83% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment?s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scient

Fundamental Ratios
Shares Outstanding124.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -14.05% Sales Growth - Q/Q-2.02% P/E
P/E To EPS Growth P/S1.61 P/BV6.33 Price/Cash Per Share
Price/Free Cash Flow53.01 ROA2.88% ROE18.13% ROI3.43%
Current Ratio1.79 Quick Ratio1.4 Long Term Debt/Equity6.45 Debt Ratio0.77
Gross Margin33.9% Operating Margin14.77% Net Profit Margin4.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities209 M Cash From Investing Activities-240.3 M Cash From Operating Activities94.7 M Gross Profit152.2 M
Net Profit31.5 M Operating Profit65.8 M Total Assets2.97 B Total Current Assets653.1 M
Total Current Liabilities365.4 M Total Debt1.88 B Total Liabilities2.51 B Total Revenue446.6 M
Technical Data
High 52 week58.05 Low 52 week29.84 Last close49.2 Last change1.78%
RSI47.88 Average true range1.05 Beta1.08 Volume419.58 K
Simple moving average 20 days0.56% Simple moving average 50 days-5.07% Simple moving average 200 days6.17%
Performance Data
Performance Week3.14% Performance Month-2.73% Performance Quart-8.48% Performance Half15.6%
Performance Year18.64% Performance Year-to-date57.79% Volatility daily1.53% Volatility weekly3.41%
Volatility monthly6.99% Volatility yearly24.22% Relative Volume271.85% Average Volume747.83 K
New High New Low


2020-06-01 11:11:00 | Is Catalent a Buy?

2020-05-28 16:16:00 | Catalent, Inc. to Present at June 2020 Virtual Investor Conferences

2020-05-27 11:22:49 | 5 Companies Reach 52-Week Highs

2020-05-21 00:00:00 | Catalent Announces Acquisition of Japanese Facility to Provide Local and Global Clinical Supply Solutions

2020-05-14 11:51:09 | Coronavirus Vaccine Progress Accelerates

2020-05-13 12:25:16 | Catalent CTLT Stock Is Shining Bright During the Darkness of Coronavirus

2020-05-12 09:04:42 | Is Catalent CTLT Stock a Good Buy During Covid-19 Uncertainty?

2020-05-09 13:23:00 | Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine

2020-05-08 18:55:54 | Pfizer to outsource some drug production, focus on coronavirus vaccine

2020-05-08 16:05:00 | Catalent, Inc. to Present at May 2020 Virtual Investor Conferences

2020-05-06 08:29:42 | Edited Transcript of CTLT earnings conference call or presentation 5-May-20 12:15pm GMT

2020-05-06 07:40:00 | Catalent Expects to Finish Fiscal 2020 Strong Amid Coronavirus Pandemic

2020-05-05 15:31:32 | Catalent Inc CTLT Q3 2020 Earnings Call Transcript

2020-05-05 09:15:01 | Catalent CTLT Q3 Earnings and Revenues Beat Estimates

2020-05-05 07:28:00 | Catalent, Inc. Reports Third Quarter Fiscal 2020 Results

2020-05-04 08:46:00 | Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

2020-05-03 09:23:13 | What Is Catalent's NYSE:CTLT P/E Ratio After Its Share Price Rocketed?

2020-04-30 16:30:00 | Catalent Announces Next Generation of Cell & Gene Therapy Leadership

2020-04-30 11:40:03 | PCRX or CTLT: Which Is the Better Value Stock Right Now?

2020-04-29 14:02:00 | Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal

2020-04-29 08:00:00 | Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

2020-04-28 12:34:04 | Catalent CTLT Reports Next Week: What to Expect

2020-04-15 16:05:00 | Catalent, Inc. Announces Third Quarter Fiscal Year 2020 Earnings Conference Webcast

2020-04-15 06:49:55 | A Rising Share Price Has Us Looking Closely At Catalent, Inc.'s NYSE:CTLT P/E Ratio

2020-04-13 19:44:00 | Catalent Publishes Fiscal 2019 Corporate Responsibility Report

2020-03-23 00:12:02 | Do Hedge Funds Love Catalent Inc CTLT?

2020-03-17 07:07:33 | What Does Catalent, Inc.'s NYSE:CTLT P/E Ratio Tell You?

2020-03-17 06:48:52 | A Sliding Share Price Has Us Looking At Catalent, Inc.'s NYSE:CTLT P/E Ratio

2020-03-09 18:45:00 | Catalent, Inc. to Present at the Barclays Global Healthcare Conference

2020-03-06 11:57:11 | Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.

2020-02-28 16:32:11 | Catalent Pharma Solutions, Inc. -- Moody's upgrades Catalent's senior secured rating to Ba2, affirms B1 CFR; the outlook remains stable

2020-02-20 13:04:00 | Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2028

2020-02-19 16:16:22 | Catalent Pharma Solutions, Inc. -- Moody's assigns B3 rating to Catalent's notes offering

2020-02-19 07:21:54 | The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

2020-02-19 02:55:00 | Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028

2020-02-18 16:05:00 | Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2020-02-16 16:07:00 | Top Insider Buys Highlight for the Week of Feb. 14

2020-02-10 16:15:00 | Catalent Completes Acquisition of MaSTherCell

2020-02-05 05:54:38 | US$70.88 - That's What Analysts Think Catalent, Inc. Is Worth After These Results

2020-02-04 07:51:48 | The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

2020-02-03 18:48:00 | Catalent, Inc. Announces Pricing of Public Offering of Common Stock

2020-02-03 16:39:06 | Edited Transcript of CTLT earnings conference call or presentation 3-Feb-20 1:15pm GMT

2020-02-03 16:12:00 | Catalent, Inc. Announces Public Offering of Common Stock

2020-02-03 10:32:20 | Catalent To Buy Cell Therapy CDMO MasTherCell For $315M

2020-02-03 08:55:01 | Catalent CTLT Matches Q2 Earnings Estimates

2020-02-03 07:30:00 | Catalent, Inc. Reports Second Quarter Fiscal 2020 Results

2020-02-03 07:29:00 | Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform

2020-01-27 12:30:05 | Catalent CTLT Reports Next Week: What You Should Expect

2020-01-27 07:16:44 | Calculating The Fair Value Of Catalent, Inc. NYSE:CTLT

2020-01-16 16:15:00 | Catalent Further Strengthens Biologics Business with Key Senior Appointments